论文部分内容阅读
目的 :研究雷公藤多甙 (TⅡ)治疗哮喘的机制。方法 :选择中、重度哮喘发作期患者 30例 ,随机分成 3组。A组 :TⅡ 治疗组 ,B组 :泼尼松龙治疗组 ,C组 :哮喘对照组。治疗前和治疗 4周后分别用流式细胞仪 (FCM )测定外周血CD4 +、CD8+T淋巴细胞数 ,用酶联免疫吸附法 (ELISA)测血清白细胞介素 5(IL 5)的浓度。结果 :A组CD4 +T淋巴细胞由治疗前的 0 4 62± 0 0 35降至 0 4 36± 0 0 39(P <0 0 1) ,CD8+T淋巴细胞由治疗前的 0 2 0 1± 0 0 4 5升至 0 2 53± 0 0 4 3(P <0 0 1) ,血清IL 5中位浓度由 65 3ng/L降至10 9ng/L(P <0 0 1)。B组各指标治疗后变化与A组相似 ,而C组各指标治疗后均无明显改变。患者血清IL 5浓度与外周血CD4 +T淋巴细胞数成正相关 (r =0 61,P <0 0 1)。结论 :TⅡ 通过调节哮喘患者T淋巴细胞亚群的紊乱 ,抑制IL 5的生成而对哮喘炎症产生治疗作用。
Objective: To study the mechanism of Tripterygium glycosides (TII) in the treatment of asthma. Methods: Thirty patients with moderate or severe asthma attack were randomly divided into three groups. Group A: TII treatment group, B group: prednisolone treatment group, C group: asthma control group. Before treatment and after 4 weeks of treatment, the number of CD4 + and CD8 + T lymphocytes in peripheral blood was measured by flow cytometry (FCM), and the concentration of serum interleukin 5 (IL 5) was measured by enzyme-linked immunosorbent assay (ELISA) . Results: The percentage of CD4 + T lymphocyte subsets in group A decreased from 0 42 62 ± 0 0 35 before treatment to 0 366 0 0 39 (P 0 01), while CD 8 + T lymphocytes decreased from 0 2 0 1 (P <0.01). The median concentration of serum IL 5 decreased from 65 3 ng / L to 10 9 ng / L (P <0.01). After treatment, the change of each index in group B was similar to that in group A, but there was no significant change in each index in group C after treatment. Serum levels of IL-5 were positively correlated with CD4 + T lymphocytes in peripheral blood (r = 0 61, P <0.01). CONCLUSION: TII has a therapeutic effect on the inflammation of asthma by regulating the disorder of T lymphocyte subsets and inhibiting the production of IL-5 in asthmatic patients.